Nouscom Secures $67.5 Million in Series C Funding for Groundbreaking Cancer Immunotherapies

Nouscom, a pioneering private clinical-stage immuno-oncology company, has successfully raised $67.5 million in its latest funding round, bolstering its mission to revolutionize cancer treatment with innovative immunotherapies. Established in 2015 and headquartered in Basel, Switzerland, with operational ties to Rome, Nouscom focuses on developing both off-the-shelf and personalized cancer therapeutics using proprietary viral vectors, which have shown high immunogenicity in clinical settings. This impressive financial backing will propel the advancement of Nouscom's promising clinical pipeline, including its flagship candidate NOUS-209, currently undergoing randomized phase 2 trials aimed at treating advanced MSI-H colorectal cancer in combination with pembrolizumab. Furthermore, the company is conducting a Phase 1b study of NOUS-209 as a monotherapy for Lynch Syndrome carriers—a groundbreaking approach designed to potentially intercept cancer before onset—in collaboration with the National Cancer Institute. In addition to NOUS-209, Nouscom is also committed to its second clinical program, NOUS-PEV, which targets advanced cancers with significant unmet needs. Notably, the company has further strengthened its portfolio by exclusively out-licensing VAC-85135, an off-the-shelf immunotherapy, to Janssen Oncology, currently under evaluation in a Phase 1 trial for Myeloproliferative Neoplasms. With support from an impressive consortium of international life sciences investors—including 5AM, Andera Partners, and EQT Life Sciences—Nouscom has raised a total of $130 million to date, positioning the company at the forefront of oncology innovation. For further details about Nouscom and its groundbreaking therapies, visit www.nouscom.com.